PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
GFC Life Science has posted four consecutive quarters of revenue growth and improving profit since its Q3 2025 loss through Q2 2026, though the gap versus its original listing guidance remains a key watch point.
2025 consolidated revenue was KRW 17.71 billion with operating profit of KRW 386 million (2.2% margin), a sharp decline in margin from the prior year.
After an operating loss of KRW 283 million in Q3 2025, both revenue and operating profit improved sequentially through Q2 2026.
The company expanded its product and distribution portfolio by launching an HA filler in February 2026 and its own derma brand 'fmk' in March 2026.
2025 results fell well short of the neutral-scenario guidance (KRW 23 billion revenue) presented at listing, leaving a credibility overhang.
Equity moved from a capital deficit in 2023 to consecutive increases in 2024-2025, while the debt ratio fell from 84.0% in 2024 to 42.2% in 2025.
GFC Life Science, founded in 2002, is a bio and cosmetics materials specialist built around skin microbiome and plant-derived exosome technology.
The business spans four segments-bio materials, exosomes, skin boosters, and clinical services-with 2024 revenue mix of 54.5% bio materials, 24.0% clinical services, 15.1% skin boosters, and 6.4% exosomes.
The bio materials unit supplies cosmetics brands using a proprietary strain library, while the clinical division conducts human application tests for cosmetics involving dermatologists.
The exosome unit handles boosting, isolation, and verification in-house and has developed a hybrid exosome platform combining elastic liposomes, with potential extension into medical devices such as wound dressings beyond skin boosters.
In February 2026 the company launched a hyaluronic acid (HA) filler called GFCCELL Luxe Filler domestically, broadening its portfolio from skin-booster-centric business into a full medical-aesthetic lineup.
The filler is being distributed through a partnership with Person Healthcare to build a domestic clinic sales network. In March 2026 the company launched its own derma brand 'fmk,' entering the B2C market with products built on high-function ingredients such as PDRN, vitamin C, and NMN.
The company exports bio materials to numerous countries including the United States, Europe, and China, with Kolmar BNH, Hyundai Bioland, Daebong LS, and Bio FD&C cited as key comparable companies. It moved from KONEX to KOSDAQ on June 30, 2025.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | — | — | — |
| 2025Q3 | ₩4.2B | -₩300M | −6.8% |
| 2025Q4 | ₩4.6B | ₩79,690,975 | 1.8% |
| 2026Q1 | ₩5B | ₩500M | 9.2% |
| 2026Q2 | ₩5.5B | ₩600M | 10.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2023 | ₩15.4B | ₩700M | ₩2.1B | 4.6% | — | −1718.9% |
| 2024 | ₩16.8B | ₩1.7B | -₩5.9B | 10.1% | −54.6% | 84.0% |
| 2025 | ₩17.7B | ₩400M | ₩600M | 2.2% | 2.3% | 42.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-07
2025 consolidated revenue rose modestly to KRW 17.71 billion from KRW 16.80 billion in 2024, but operating profit fell sharply to KRW 386 million from KRW 1.70 billion, pushing the operating margin down from 10.1% to 2.2%.
Analyst commentary attributes this to overseas revenue recognition for finished products such as skin boosters being pushed back from plan, combined with listing-related and global distribution build-out costs front-loaded into SG&A.
Net income attributable to owners swung from a loss of KRW 5.95 billion in 2024 (reflecting a derivative valuation loss tied to redeemable convertible preferred shares) to a profit of KRW 555 million in 2025.
By quarter, Q3 2025 revenue was KRW 4.18 billion with an operating loss of KRW 283 million and a net loss of KRW 288 million, marking what appears to be the trough, before Q4 2025 improved to revenue of KRW 4.55 billion, operating profit of KRW 80 million, and net profit of KRW 469 million.
Q1 2026 continued the growth trend with revenue of KRW 5.04 billion, operating profit of KRW 464 million, and net profit of KRW 477 million, while Q2 2026 posted revenue of KRW 5.46 billion, operating profit of KRW 581 million, and net profit of KRW 417 million-four straight quarters of revenue growth and three straight quarters of profitability.
Equity expanded from a capital deficit of KRW 1.16 billion in 2023 to KRW 10.9 billion in 2024 and KRW 23.8 billion in 2025, reflecting the conversion of redeemable convertible preferred shares into common stock and IPO proceeds during the KOSDAQ transfer listing process.
The debt ratio, a largely meaningless -1718.9% in 2023 due to the capital deficit, fell substantially from 84.0% in 2024 to 42.2% in 2025, indicating improved financial structure.
Operating cash flow declined from KRW 2.27 billion in 2023 and KRW 2.97 billion in 2024 to KRW 1.37 billion in 2025, a moderation in cash generation despite revenue growth that warrants continued monitoring.
The global microbiome market is estimated to grow from USD 6.18 billion in 2022 at a 13.1% CAGR to USD 10.09 billion by 2026. The exosome technology market is projected to expand from USD 47.3 billion in 2023 at a 24.8% CAGR to USD 343.5 billion by 2031.
In Korea, however, the Ministry of Food and Drug Safety generally prohibits the use of human-derived cells and their culture media as cosmetic ingredients, a regulatory backdrop that aligns with the company's plant- and microbe-derived material strategy.
Some analysis also points to premium skincare shifting from brand- and marketing-driven competition toward one centered on scientific evidence and efficacy data for ingredients.
In the fourth-generation skin booster market, demand is growing among dermatology and plastic surgery clinics for products focused on extracellular matrix (ECM) regeneration rather than the conventional collagen-induction approach.
Kolmar BNH, Hyundai Bioland, Daebong LS, and Bio FD&C are cited as key comparable companies, and the fact that GFC Life Science's share price performance over a recent three-month period lagged these peers is a relevant reference point for assessing its industry positioning.
The domestic filler market is a mature, multi-player competitive field, and as a new entrant the company is pursuing early revenue visibility through a distribution partnership.
At the time of its KOSDAQ transfer listing, the company presented estimates in its securities registration statement of KRW 29.8 billion in revenue for 2026 and KRW 42.4 billion for 2027.
However, since 2025 results fell short of the listing-time guidance (a neutral-scenario revenue of KRW 23 billion), how closely 2026-and-beyond results approach these figures is flagged as a key watch point.
Some in the securities industry have suggested that listing- and distribution-network-build-out costs front-loaded in 2025 could be absorbed as revenue growth continues in 2026, allowing operating leverage to normalize.
The filler launch originally slated for early 2026 actually occurred in February, and is cited as a factor that could improve margins through a better product mix. The company is also accelerating export growth, with Q1 2026 export revenue rising 95.8% to KRW 840 million from KRW 430 million a year earlier.
Product certification procedures are underway in markets including the United States, Japan, and Brazil, leaving room for overseas revenue share to expand further once certifications are completed.
The B2C brand fmk is pursuing expansion across online and offline distribution channels, and whether it becomes a meaningful new growth driver remains to be confirmed going forward.
At listing, the IPO price was set using an average price-to-earnings ratio of 21.88x from comparable companies including Kolmar BNH, Hyundai Bioland, Daebong LS, and Bio FD&C, providing a historical reference band against which the current PER level can be compared.
Equity moved from a capital deficit in 2023 through consecutive expansions in 2024-2025, a period during which the relationship between share price and net assets was itself being re-established.
Net income swung from a large loss in 2024 (reflecting a derivative valuation loss tied to redeemable convertible preferred shares) to profitability in 2025, with quarterly profitability continuing into 2026, so the earnings-based data underlying valuation has been on an improving trajectory.
There has been no dividend payout in recent fiscal years, leaving the stock at a relative disadvantage versus other dividend-paying peers in the sector for income-oriented investors.
The fact that the proportion of freely tradable shares expanded over time following the listing is another factor worth considering alongside share price and supply-demand dynamics.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-07
Following an operating loss of KRW 283 million in Q3 2025, operating profit improved sequentially to KRW 80 million in Q4 2025, KRW 464 million in Q1 2026, and KRW 581 million in Q2 2026. Revenue also rose for four consecutive quarters, from KRW 4.18 billion to KRW 5.46 billion over the same period. Net income likewise remained profitable for three straight quarters following the Q3 2025 net loss.
The February 2026 HA filler launch expanded the business from a skin-booster focus into a full medical aesthetics lineup. In March of the same year, the company also entered the B2C market with its own derma brand fmk.
Expansion into medical device areas such as wound dressings is also being discussed, indicating an ongoing diversification of the product lineup.
Q1 2026 export revenue rose 95.8% year-on-year to KRW 840 million. The company exports bio materials to numerous countries including the United States, Europe, and China, with certification procedures underway in the U.S., Japan, and Brazil.
It is exposed to an industry cycle in which the global microbiome and exosome markets are estimated to grow at 13.1% and 24.8% annually, respectively.
2025 actual revenue of KRW 17.71 billion and operating profit of KRW 386 million fell well short of the neutral-scenario guidance presented at listing (revenue of KRW 23 billion, operating profit of KRW 4.9 billion). Net income also reached only KRW 555 million versus a target of KRW 3.8 billion. This gap is a relevant reference point when assessing the credibility of the company's future projections.
Equity stood at a capital deficit of KRW 1.16 billion in 2023, and the debt ratio in 2024 at 84.0% was higher than the sector average. Although the debt ratio fell to 42.2% in 2025, a substantial portion of this improvement reflects IPO proceeds inflow.
The proportion of freely tradable shares expanded over time following listing, and as a small-cap stock it can be exposed to supply-demand volatility.
The 2025 operating margin fell sharply to 2.2% from 10.1% in 2024. Annual revenue scale of roughly KRW 17.7 billion remains small in absolute terms, leaving results potentially sensitive to individual events.
New businesses such as the filler and fmk brand are still at an early stage, and the timing of a meaningful revenue contribution relative to existing operations remains uncertain.
A key factor behind the 2025 revenue shortfall was identified as delays in overseas certification affecting the recognition of finished-product export revenue.
If certification procedures currently underway in markets such as the U.S., Japan, and Brazil are further delayed, revenue recognition timing could again be pushed back. New medical device products such as the filler are also not free from regulatory approval and classification review risk.
The company experienced a capital deficit in 2023 and recorded a large net loss in 2024 due to a derivative valuation loss related to redeemable convertible preferred shares. This kind of capital structure volatility is a factor that could recur in connection with future capital raises or related-party transactions.
The structure whereby the proportion of freely tradable shares expands over time is a potential source of share overhang.
Competition is intensifying as numerous companies enter the fourth-generation skin booster and exosome materials markets. Given the company's history of significantly missing prior listing guidance, building market confidence in future revenue and profit targets may take time.
A resource gap versus larger competitors such as Kolmar BNH is also a variable that could affect the pace of business expansion.
The next scheduled monthly revenue disclosure the company has voluntarily filed, offering an early read on Q3 revenue trends.
Whether Q3 2026 revenue and operating profit improve further from Q2 (KRW 5.46 billion and KRW 581 million) and the four-quarter growth streak continues needs to be confirmed.
The progress of domestic clinic distribution expansion for the GFCCELL Luxe Filler and the extent to which it contributes to revenue should be monitored.
Whether product certifications underway in the U.S., Japan, and Brazil are completed, and the resulting timing of initial orders and export revenue recognition, should be confirmed.
How closely full-year 2026 results approach the estimate presented at listing (KRW 29.8 billion in revenue) could be a turning point for assessing guidance credibility.
GFC Life Science has shown sequential improvement in revenue and operating profit each quarter from its Q3 2025 loss through Q2 2026, and has sustained profitability after swinging from a large net loss in 2024 to a profit in 2025.
The company is broadening its business portfolio with new products such as the filler and its own fmk brand, while also pursuing export growth and overseas certification in parallel.
That said, the history of 2025 results falling well short of listing-time guidance, past capital structure volatility including a capital deficit and a derivative valuation loss, and a still-low absolute operating margin are factors that warrant balanced consideration.
Key items to watch going forward include whether growth continues through monthly revenue disclosures and Q3 results, when new product lines begin contributing meaningfully to revenue, and how closely full-year 2026 results approach the estimates presented at listing.
As all of this data will be updated over time, readers are encouraged to check the latest disclosures and quarterly results directly before forming any investment judgment.
Report written 2026-09-08 · Data as of 2026-09-07
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.